• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Gerresheimer (XTRA:GXI) Cheap On Its CEO Exit Or Is The Uncertainty Priced In?

    Simply Wall St·08/25/2026 12:25:54
    语音播报

    The resignation of interim CEO Uwe Rohrhoff from Gerresheimer (XTRA:GXI) has put a fresh spotlight on the company’s leadership path and what this change could mean for investors assessing the stock today.

    See our latest analysis for Gerresheimer.

    Against this leadership change, Gerresheimer’s 1 month share price return of 6.62% and 3 month share price return of 2.34% point to modest positive momentum. However, the 1 year total shareholder return has declined 38.79% and the 5 year total shareholder return has declined 67.73%.

    If this kind of leadership reshuffle has you reassessing your holdings, it can be useful to widen your view with other opportunities in the market and check out 114 top founder-led companies

    So is Gerresheimer’s latest share price move and leadership change pointing to a business that the market has mispriced, or just a short term swing in sentiment? The next step is to look closely at its valuation.

    Most Popular Narrative: 10.9% Overvalued

    Gerresheimer’s most followed narrative puts fair value at €25.26 using a 10.34% discount rate, compared with the last close of €28.02, which creates a clear valuation gap to assess.

    The acquisition of Bormioli Pharma is expected to propel Gerresheimer's revenues from €2 billion in 2024 to around €2.5 billion in 2025, while also enhancing the company's adjusted EBITDA margin to approximately 22%. This marks a significant step forward in terms of revenue growth and profitability enhancement.

    Read the complete narrative.

    Want to see how this expected revenue step up and margin reset are stitched together into one valuation story? The key levers are growth, profitability and the future earnings multiple that underpins that €25.26 figure.

    Result: Fair Value of €25.26 (OVERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, there are still clear risks to this Gerresheimer narrative, including integration challenges around Bormioli Pharma, as well as ongoing concerns about delayed results and accounting quality.

    Find out about the key risks to this Gerresheimer narrative.

    Another View On Gerresheimer’s Valuation

    The analyst narrative suggests Gerresheimer is around 10.9% overvalued at a fair value of €25.26. Our DCF model points in the opposite direction. It puts fair value closer to €47.37, which means the current €28.02 share price is trading at a large discount. Which story do you think fits the risks and execution track record best?

    For a closer look at how the cash flow assumptions compare with that €47.37 figure, Look into how the SWS DCF model arrives at its fair value.

    GXI Discounted Cash Flow as at Aug 2026
    GXI Discounted Cash Flow as at Aug 2026

    Next Steps

    Seen enough to sense that Gerresheimer’s story is finely balanced between concern and optimism? Take a closer look at the numbers and risks yourself, then weigh them against the potential rewards with 3 key rewards and 1 important warning sign

    Looking For More Investment Ideas Beyond Gerresheimer?

    If Gerresheimer has sharpened your focus on valuation and risk, do not stop here. Use the Simply Wall Street Screener to line up your next potential opportunities.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.